China’s state-run medicare program recently failed to reach an agreement with Pfizer to import more Paxlovid, claiming the COVID-19 treatment drug is too expensive. This is despite the drug being offered to the state at a reduced rate in comparison with that offered to other developed countries. Lack of Paxlovid will leave only Azvudine, an
https://www.theepochtimes.com/school-where-6-year-old-boy-shot-teacher-reopens-with-added-security_5019862.html